Literature DB >> 9824618

Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.

C Haas1, C Ertel, R Gerhards, V Schirrmacher.   

Abstract

We demonstrate in this study that infection of tumor cells by Newcastle Disease Virus (NDV) leads to changes in tumor cell surface adhesiveness and tumor immune costimulatory function. While adsorbtion of virions to the cell surface occurs after short-term (10 min) incubation and leads to cells expressing viral antigens at low antigen density (LAD), viral replication in the cytoplasm occurs within 5-24 h leading to tumor cells expressing viral antigens at high antigen density (HAD) as shown by quantitative FACS flow cytometry. Virus infected tumor cells showed an increased adhesiveness for erythrocytes and lymphocytes. When IL-2 preactivated human lymphocytes with cytotoxic potential were coincubated with 51Cr-labeled NDV-infected or non-infected human colon carcinoma cells increased lysis of the virus infected targets was observed. The virus mediated cell adhesion could be inhibited by monoclonal antibody (mAb) against the hemagglutinin-neuraminidase (HN) molecule but not by antibody against the fusion protein. HN cDNA transfectants also mediated increased lymphocyte adhesion in comparison to wild-type or neo-vector transfected control cells. Further experiments demonstrated that not only the adhesion domain of HN but also the neuraminidase plays a role in cell-cell interactions. A comparison of an NDV neuraminidase mutant of the strain Australian Victoria (AV-L1) with the parental AV strain revealed pronounced differences in their capacity to mediate lymphocyte binding and costimulatory activity. The mutant with highly decreased neuraminidase activity was very similar to NDV Ulster in adhesive and costimulatory activity while the parental line with high neuraminidase activity was negative for both functions. Costimulatory effects of NDV Ulster and AV-L1 were revealed when virions and suboptimal concentrations of anti-CD3 mAbs were coated to microtiter plates for induction of murine CD4 T cell proliferation. In human autologous mixed lymphocyte-tumor cell cultures up-regulation of T cell activation markers CD69 and CD25 was seen with NDV modified but not with non-modified tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824618     DOI: 10.3892/ijo.13.6.1105

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  T cell memory, anergy and immunotherapy in breast cancer.

Authors:  Volker Schirrmacher; Markus Feuerer; Philipp Beckhove; Thorsten Ahlert; Viktor Umansky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

3.  Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.

Authors:  Wei Liang; Hui Wang; Tie-Mie Sun; Wen-Qing Yao; Li-Li Chen; Yu Jin; Chun-Ling Li; Fan-Juan Meng
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

4.  Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Authors:  D Zamarin; A Vigil; K Kelly; A García-Sastre; Y Fong
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

Review 5.  Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Clin Dev Immunol       Date:  2011-03-01

6.  Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Authors:  Dmitriy Zamarin; Rikke B Holmgaard; Jacob Ricca; Tamar Plitt; Peter Palese; Padmanee Sharma; Taha Merghoub; Jedd D Wolchok; James P Allison
Journal:  Nat Commun       Date:  2017-02-13       Impact factor: 14.919

7.  Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification.

Authors:  Lisa A Santry; Renaud Jacquemart; Melissa Vandersluis; Mochao Zhao; Jake M Domm; Thomas M McAusland; Xiaojiao Shang; Pierre M Major; James G Stout; Sarah K Wootton
Journal:  BMC Biotechnol       Date:  2020-06-17       Impact factor: 2.563

Review 8.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

Review 9.  Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.

Authors:  Amish C Shah; Dale Benos; G Yancey Gillespie; James M Markert
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

10.  Live attenuated measles virus vaccine therapy for locally established malignant glioblastoma tumor cells.

Authors:  Ahmed M Al-Shammari; Farah E Ismaeel; Shahlaa M Salih; Nahi Y Yaseen
Journal:  Oncolytic Virother       Date:  2014-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.